Advaxis and Personalis Announce Research Agreement to Deploy ImmunoID NeXT Platform in the ADXS-503 Clinical Program

NEXT STORY
SELLAS Announces Enrollment of First Patient in Phase 1 Trial of Galinpepimut-S (GPS) in Combination with Nivolumab (Opdivo®) in Patients with Malignant Pleural Mesothelioma (MPM)
PREV STORY
Next-Generation Sequencing Market Size Report 2020 – 2026 | NGS Industry Share, Growth, Insights and Forecast
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Orion Group Financial Statement documents 2016 and Corporate Governance Statement published

ORION CORPORATION         STOCK EXCHANGE RELEASE 27 FEBRUARY 2017 at 13.00 EET                       Orion Group ...

author_avatar
NASDAQ Market News

Eurobio Scientific acquires Dendritics, a company specializing in antibody development and manufacture

Eurobio Scientific acquires Dendritics,  a company specializing in antibody development and manufacture This strategic ...

author_avatar
NASDAQ Market News

Mustang Bio and City of Hope Announce Initiation of Phase 1 Clinical Trial of MB-101 (IL13Rα2-specific CAR T cells) to Treat Leptomeningeal Brain Tumors

author_avatar
NASDAQ Market News